<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Dowell, Masha</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">Fonarow, Gregg C.</style></author></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">Rapid Reperfusion Therapy in Acute Ischemic Stroke Reduces Complications and Improves Outcomes</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2014</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2014-04-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">16-17</style></pages><abstract><style  face="normal" font="default" size="100%">The American Heart Association (AHA)/American Stroke Association (ASA) guidelines recommend a door-to-needle (DTN) time of =60 minutes for reperfusion therapy for acute ischemic stroke patients [Jauch EC et al. Stroke 2013]. The rapid treatment is important for improving stroke outcome, but many studies have concluded that this time frame has been met by &lt;30% of intravenous tissue plasminogen activator (t-PA)-treated stroke patients. This article discusses the principal results from the Target: Stroke Initiative, a national program organized by the AHA/ASA, which addresses this timing dilemma by increasing the proportion of stroke patients with DTN time frames of &lt;60 minutes.</style></abstract><number><style face="normal" font="default" size="100%">1</style></number><volume><style face="normal" font="default" size="100%">14</style></volume></record></records></xml>